Vivos Therapeutics, Inc. recently filed an 8-K with the Securities and Exchange Commission (SEC) detailing a significant agreement with SOD Sciences, Inc. The filing, dated October 15, 2026, outlines a mutual stock purchase and asset exchange agreement that could shape the future of the company.

This filing is important for investors and stakeholders as it highlights Vivos Therapeutics' strategic moves in the medical and health technology sectors. The agreement could enhance the company's product offerings and market reach.

Background on Vivos Therapeutics

Vivos Therapeutics, Inc. is a company based in Littleton, Colorado, focused on developing innovative solutions for sleep-disordered breathing and other related conditions. The company operates in the surgical and medical instruments industry, specifically targeting treatments that improve patient outcomes. The SEC Form 8-K is used to report major events that shareholders should know about, including significant agreements, changes in management, or financial results.

Details of the Filing

According to the filing (Accession Number: 0001493152-26-047158), Vivos entered into a Mutual Stock Purchase and Asset Exchange Agreement with SOD Sciences, Inc. on October 14, 2026. Under this agreement, Vivos will issue 12,000 shares of a new series of preferred stock, designated as "Series C Convertible Preferred Stock," in exchange for:

  • 2,907,338 shares of SOD common stock, representing at least 11% of SOD's fully diluted capital stock.
  • A 50% co-ownership interest in the ReBalU Protocol, a test/treat/retest platform and related intellectual property.

The closing of this agreement is expected to occur on October 15, 2026. Notably, no cash consideration will be exchanged between the two parties.

The filing also mentions that the terms of the Series C Preferred will rank senior to Vivos' common stock regarding dividends and liquidation rights. Each share of Series C Preferred will be convertible into common stock at a fixed price of $0.15 per share, potentially allowing for the issuance of up to 80 million shares of common stock upon conversion.

Impact of the Filing

This agreement may significantly impact various stakeholders, including investors, employees, and patients. For investors, the acquisition of SOD's assets and stock could enhance Vivos' market position and product offerings. Employees may see new opportunities for growth and innovation as the company expands its capabilities. Patients could benefit from improved treatment options stemming from the collaboration with SOD Sciences.

What's Next?

The filing does not specify what happens next beyond the expected closing of the agreement on October 15, 2026. However, Vivos is required to include a proposal in its upcoming proxy statement for stockholder approval concerning the issuance of common stock upon conversion of the Series C Preferred in excess of the exchange cap.